Research Article

Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin

Shalaka S. Hampras,1 Rhianna A. Reed,1 Spencer Bezalel,2 Michael Cameron,2 Basil Cherpelis,3,4 Neil Fenske,3,4 Vernon K. Sondak,5 Jane Messina,3,5,6 Massimo Tommasino,7 Tarik Gheit,7 and Dana E. Rollison1

1Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA
2University of South Florida, Morsani College of Medicine, Tampa, Florida, USA
3Department of Dermatology, University of South Florida, College of Medicine, Tampa, FL, USA
4Department of Cutaneous Surgery, University of South Florida, College of Medicine, Tampa, FL, USA
5Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, Florida, USA
6Departments of Pathology and Cell Biology, University of South Florida, College of Medicine, Tampa, FL, USA
7Infections and Cancer Biology Group, International Agency for Research on Cancer-World Health Organization, Lyon 69372, France

Correspondence should be addressed to Shalaka S. Hampras; shalaka.hampras@moffitt.org

Received 25 August 2016; Revised 5 October 2016; Accepted 16 October 2016

Academic Editor: Günther Hofbauer

Copyright © 2016 Shalaka S. Hampras et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The role of cutaneous human papillomavirus (HPV) infection in the development of subsequent cutaneous squamous cell carcinoma (SCC) is unknown. Pathologically confirmed cases of SCC (n = 150) enrolled in a previously conducted case-control study were included in a retrospective cohort study to examine the association of cutaneous HPV at the time of SCC diagnosis with the risk of subsequent SCC development. Data on HPV seropositivity, HPV DNA in eyebrow hairs (EB) and SCC tumors were available from the parent study. Incidence of subsequent SCC was estimated using person-years of follow up. Cox Proportional Hazards ratios were estimated to evaluate the associations of both, HPV seropositivity and HPV DNA positivity with subsequent SCC. The five year cumulative incidence of subsequent SCC was 72%. Seropositivity to cutaneous HPV was not associated with the risk of subsequent SCC (HR = 0.83, 95% CI = 0.41–1.67). Any beta HPV infection in EB was associated with reduced risk (HR = 0.30, 95% CI = 0.11–0.78) of subsequent SCC among cases who were positive for beta HPV DNA in tumor tissue. Infection with beta HPV type 2 (HR = 0.32, 95% CI = 0.12–0.86) in EB was associated with reduced risk of subsequent SCC among HPV DNA positive SCCs. In conclusion, beta HPV infection was inversely associated with the risk of subsequent SCC.

1. Introduction

Keratinocyte cancer (KC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), is the most commonly diagnosed cancer in the United States [1]. While ultraviolet radiation is an established risk factor for KC [2], growing evidence suggests infection with cutaneous human papillomavirus (HPV) may increase the risk of cutaneous SCC [3–8]. We previously reported an increased risk of SCC associated with the presence of four or more types of cutaneous HPV DNA in eyebrow hairs [3]. Serological responses to genus beta HPV types were found to be associated with increased risk of SCC [4]. Further, poor tanning ability was associated with 6.9 times increased risk of SCC among those who were seropositive to beta HPV type [5]. Collectively, these findings suggest that cutaneous HPV may play a role in the pathogenesis of SCC. However, it should be noted that some previous case-control studies reporting an association between beta HPV and SCC included only primary cases of SCC [6, 9], while others [3, 4] did not differentiate between primary and subsequent SCCs. Therefore, the role of
cutaneous HPV infection in the development of subsequent SCC is unknown.

As compared to BCCs, SCCs are more likely to be clinically aggressive with a propensity to recur and metastasize [1, 10]. As reviewed previously, patients with metastatic SCC have less than 20% survival rate over 10 years [1]. Varying recurrence rates for SCC have been reported based on the site of involvement, metastasis, and grade. In a retrospective study, 30% SCCs involving temporal bone were found to recur within an average of 5.8 months [11]. Others have reported lower SCC recurrence rates of 9–15% [12, 13]. As summarized by Alam and Ratner, risk factors for recurrence of SCCs include tumor size, site, tumor depth, perineural invasion, history of treatment for SCC, and tumor differentiation [1]. While these factors may aid in the identification of SCC cases at high risk of recurrence, they provide limited scope for intervention beyond treatment or close surveillance to prevent the recurrence of SCC.

SCC cases are also at a high risk of developing second primary SCCs. In a large population based study of over 25,000 Swedish SCC cases, a significantly increased risk of second primary SCC was observed (standardized incidence ratio = 15.6) [14]. Meta-analyses results have shown that the risk of developing SCC subsequent to an “index” SCC was 18% [15]. As cautioned by Marcil and Stern, some of the previous studies examining the risk of a subsequent SCC included index SCC cases with a history of >1 SCC or did not provide such information. Thus, the index SCCs may have comprised both first and recurrent SCCs [15]. The high morbidity associated with development of subsequent SCCs warrants further research.

Given the increased risk of SCC observed in association with cutaneous HPV infection as described above, it is reasonable to hypothesize that patients with SCCs associated with cutaneous HPV infection are more likely to develop subsequent SCCs compared to patients with SCCs that are not associated with HPV.

Using a subset of SCC cases (n = 150) from our previously conducted study [3, 4], we conducted a retrospective cohort study to examine the association between cutaneous HPV infection at the time of SCC diagnosis in the parent study with the risk of subsequent SCC. Infection with cutaneous HPV was assessed using three biomarkers: serum antibodies to HPV, presence of HPV DNA in eyebrow hairs, and presence of HPV DNA in SCC tumors.

2. Materials and Methods

2.1. Study Design and Population. The study population has been described previously [3, 4, 16]. Briefly, a clinic based case-control study was conducted at Moffitt Cancer Center in Tampa, Florida, in 2007–2009. Histologically confirmed cases of SCC (n = 173) were identified through the University of South Florida (USF) Dermatology Clinic. Both newly diagnosed primary SCCs and cases with a prior history of SCC were included in the case group. Controls included patients without history of any type of cancer and who were negative for skin cancer based on a full-body screening exam at the time of enrollment. Of the 173 SCC cases enrolled in the parent case-control study, 150 SCC cases were followed through 2014. The remaining cases either did not return to the clinic or were only referred to USF Dermatology Clinic for Moh’s surgery. Cases without complete follow-up were similar in age and gender distribution to the cases with complete follow-up. The 150 “index” SCC cases with complete follow-up through 2014 were included in the present analyses. Serology data on 33 cutaneous HPV types, including HPV types in the alpha, beta, and gamma genera (α, β, γ), as well as beta HPV DNA (n = 25 beta HPV types) status in eyebrow hairs (n = 145) and SCC tumor tissue (n = 131), at the time of enrollment of index SCC, were available from the parent study [3, 4]. Self-reported data on demographics, smoking, alcohol consumption, and skin cancer risk factors, including history of blistering sunburns, sun exposure, and tanning ability were also available from the parent study. For the current retrospective cohort, subsequent SCC was defined as the SCC, including recurrent and second primary SCC, detected after the index SCC was diagnosed at the enrollment biopsy in the parent case-control study [3, 4]. Medical charts of index SCCs were reviewed, and data on the date of past history of SCC prior to enrollment of an index SCC case in the parent case-control study, date of subsequent SCC diagnosed after the index SCC enrollment, site and tumor dimensions of subsequent SCC, other incident keratinocyte cancers and date of last contact or death were abstracted. All participants provided written informed consent, and the study protocol was approved by the Institutional Review Board at USF.

2.2. Serology. Serum samples obtained from the index SCC cases at the time of their enrollment in the parent study were examined for antibodies to major capsid protein L1 for 33 cutaneous HPV types including genera alpha (α, 2, 3, 7, 10, 27, 57, and 77); beta [β (5, 8, 20, 24, 36), β2 (9, 15, 17, 23, 38, 107), β3 (49, 75, 76), β4 (92), and β5 (96)], gamma (γ, 4, 48, 50, 65, 88, 95, 101, 103), mu (μ), and nu (ν). As described previously [4], antibodies were detected using an enzyme-linked immunosorbent assay [17, 18] and fluorescent bead-based multiplex serology [19].

2.3. HPV DNA in Eyebrow Hairs and SCC Tumor Tissue. Measurement of HPV DNA in eyebrow hairs and fresh-frozen SCC tumors has been described in detail previously [3, 4]. Briefly, HPV DNA was extracted from eyebrow hairs and SCC tumor tissue with the QIAGEN EZI DNA Tissue Kit, and HPV genotyping was performed using a type specific multiplex assay detecting DNA from 25 genus beta HPV types (5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, and 96) [20, 21].

2.4. Statistical Analyses. Follow-up time was defined as the time interval between the date of index SCC biopsy at enrollment in the parent study and date of diagnosis of subsequent SCC or date of last contact. Five-year cumulative incidence of subsequent SCC was estimated using person-years of follow-up. Demographic, lifestyle factors, and skin cancer risk factors were compared between those who developed a subsequent SCC and those who did not, using Chi Square and Fisher’s exact tests, as appropriate. Cox Proportional Hazards
showed that “any” beta-2 HPV infection in eyebrow hairs was associated with subsequent SCC among cases who were positive for “any” beta HPV DNA in tumor tissue (Table 5). Further, species-specific analyses showed that “any” beta-2 HPV infection in eyebrow hairs was associated with 68% significantly reduced risk of subsequent SCC among tumor DNA positive index SCC cases (Table 5).

Beta HPV seropositivity was not associated with subsequent SCC after stratification by tumor beta HPV DNA status (Table 5).

Cutaneous SCCs contribute substantial morbidity due to their tendency to recur [1] and associated high risk of development of second primary malignancies of the skin and other organs [14]. With the rising incidence of SCC [22], the prevalence of recurrent and second primary SCCs will also increase contributing substantially to public health burden. It is important to identify factors predisposing to recurrent and second primary SCCs to guide development of better follow-up protocols, characterize high risk SCCs, and inform preventive strategies aimed at reducing the morbidity associated with subsequent SCCs.

In this retrospective cohort study, while no association was observed between cutaneous HPV seropositivity and the risk of subsequent SCC, a significantly inverse association was observed between cutaneous beta HPV infection in eyebrow hairs detected at the time of index SCC diagnosis and subsequent SCC development, among SCC cases with HPV DNA positive index SCC tumors. These findings are in contrast to the positive association reported between cutaneous HPV infection, measured by HPV serology and presence of HPV in eyebrow hairs, and SCC [3, 4]. However, our findings are consistent with findings from previous studies on mucosal HPV infection associated cancers. Mucosal HPV infection has been previously associated with improved survival [23–25] or reduced rate of recurrence [26] in some cancers. For example, in a small study of 41 cases, recurrence rate of nasopharyngeal carcinoma was 75% in HPV tumor DNA negative patients compared to 11% in tumor DNA positive patients [26]. Ritchie et al. reported that HPV positive oropharyngeal cancers had 70% significantly improved survival compared to HPV negative cases, with significant survival benefits for men versus women [25]. As discussed previously [25], increased sensitivity to radiation treatment and reduced occurrence of P53 mutations in HPV tumor positive cases have been suggested as possible mechanisms of improved prognosis in association with mucosal HPV infection.

In the context of cutaneous SCC, which is mainly treated by excision, it is not clear whether the underlying mechanisms of improved prognosis of HPV positive SCCs are similar to those suggested for prognosis of mucosal HPV associated cancers. Cutaneous HPV infection is thought to be involved in the initiation, but not the maintenance of SCC [27, 28]. One explanation of the observed inverse association between beta HPV infection and subsequent SCC could be that beta HPV infection in index SCC tumors may be immunogenic and could potentially stimulate host immune response that prevents the development of subsequent SCCs.

Our findings may suggest different mechanisms driving tumor progression in HPV DNA positive versus HPV DNA negative SCC cases. Immunological and genetic factors that are associated with HPV DNA negative tumors should be explored further. Previously, we showed that, among a subset of SCC cases included in the present study, single nucleotide polymorphisms (SNPs) in epidermodysplasia verruciformis
Table 1: Demographic and baseline characteristics of 150 cutaneous squamous cell carcinoma (SCC) cases.

| Variable                                                  | n (%)     |
|-----------------------------------------------------------|-----------|
| Age in years [Mean (std)]                                 | 64.4 (10.20) |
| Gender                                                    |           |
| Male                                                      | 100 (66.7) |
| Female                                                    | 50 (33.3)  |
| Race                                                      |           |
| White                                                     | 134 (100.0) |
| Other                                                     | 0 (0)     |
| Education                                                 |           |
| ≤ 12th grade                                              | 23 (17.4)  |
| >12th grade                                               | 109 (82.6) |
| Skin color                                                |           |
| Fair white                                                | 59 (44.4)  |
| Medium white                                              | 69 (51.9)  |
| Light brown                                               | 5 (3.8)    |
| Skin’s reaction to first time exposure in the sun         |           |
| A blistering sunburn                                      | 21 (16.0)  |
| A sunburn without blisters                                | 58 (44.3)  |
| A mild sunburn that becomes a tan                         | 35 (26.7)  |
| A tan with no sunburn                                     | 164 (10.7) |
| No change in skin color                                   | 3 (2.3)    |
| History of blistering sunburn prior to index SCC diagnosis|           |
| No                                                        | 29 (22.3)  |
| Yes                                                       | 101 (77.7) |
| Skin’s reaction to repeated exposure in the sun           |           |
| Unable to tan                                             | 243 (17.6) |
| It can tan if you work at it                              | 61 (46.6)  |
| It tans easily                                            | 47 (35.9)  |
| Job in sun for more than 3 months at any time in life prior to the index SCC diagnosis |           |
| No                                                        | 70 (53.0)  |
| Yes                                                       | 62 (47.0)  |
| Number of moles on the entire body                        |           |
| None                                                      | 47 (35.3)  |
| Less than 10 moles                                        | 62 (46.6)  |
| 10–25 moles                                               | 21 (15.8)  |
| More than 25 moles                                        | 3 (2.3)    |
| History of smoking                                        |           |
| Never                                                     | 40 (30.8)  |
| Ever                                                      | 90 (69.2)  |
| History of SCC                                            |           |
| No                                                        | 8 (7.2)    |
| Yes                                                       | 103 (92.8) |

genes, regulating immune response against HPV, were associated with reduced risk of beta HPV DNA positive SCC tumors [29]. These SNPs should be explored further in association with the risk of subsequent SCC.

The findings from our study should be interpreted with caution. A majority (92.8%) of index SCC cases had a history of SCC prior to their enrollment in the parent case-control study. Thus, external validity of our findings may be limited to those cases with a past history of SCC. Cutaneous HPV infection status at the diagnosis of past SCCs was unknown. Therefore, association of change in HPV infection status over time with the risk of subsequent SCCs could not be evaluated. HPV DNA status in subsequent SCC tumors detected during follow-up was not measured. Due to limited sample size, robust statistical analyses for HPV type specific association with subsequent SCC development could not be conducted. The subsequent SCCs detected in this study could be recurrent SCCs, presenting at the same anatomic site as
Table 2: Associations between baseline skin cancer risk factors and subsequent cutaneous squamous cell carcinoma (SCC).

| Variable                                                      | No subsequent SCC \(n = 59\) | Subsequent SCC \(n = 91\) | \(P\) value for Chi Square test |
|---------------------------------------------------------------|-------------------------------|---------------------------|---------------------------------|
| **Age [mean (STD)]**                                         | 62.9 (12.4)                  | 65.4 (8.4)                | 0.16\(^1\)                      |
| **Gender**                                                   |                               |                           | 0.12                           |
| Female                                                       | 24 (40.7)                    | 26 (28.6)                 |                                 |
| Male                                                         | 35 (59.3)                    | 65 (71.4)                 |                                 |
| **History of blistering sunburn prior to index SCC diagnosis** |                               |                           |                                 |
| No                                                           | 15 (28.3)                    | 14 (18.2)                 |                                 |
| Yes                                                          | 38 (71.7)                    | 63 (81.8)                 | 0.17                           |
| **Tanning ability**                                         |                               |                           |                                 |
| No                                                           | 11 (21.6)                    | 12 (15.0)                 |                                 |
| Yes                                                          | 40 (78.4)                    | 68 (85.0)                 | 0.33                           |
| **Job in sun for more than 3 months at any time in life prior to the index SCC diagnosis** |                               |                           |                                 |
| No                                                           | 31 (59.6)                    | 39 (48.7)                 | 0.22                           |
| Yes                                                          | 21 (40.4)                    | 41 (51.2)                 |                                 |
| **Smoking**                                                  |                               |                           |                                 |
| Never                                                        | 17 (32.1)                    | 23 (29.9)                 |                                 |
| Ever                                                         | 36 (67.9)                    | 54 (70.1)                 | 0.79                           |
| **Alcohol**                                                  |                               |                           |                                 |
| Never drinker                                                | 12 (23.5)                    | 15 (18.7)                 | 0.51                           |
| 1 or more drinks in past 1 year                              | 39 (76.5)                    | 65 (81.2)                 |                                 |
| **History of SCC prior to index SCC diagnosis**              |                               |                           |                                 |
| No                                                           | 7 (15.6)                     | 1 (1.5)                   |                                 |
| Yes                                                          | 38 (84.4)                    | 65 (98.5)                 | 0.007\(^2\)                    |
| **History of BCC prior to index SCC diagnosis**              |                               |                           |                                 |
| No                                                           | 7 (21.2)                     | 2 (3.6)                   | 0.01\(^2\)                     |
| Yes                                                          | 26 (78.8)                    | 53 (96.4)                 |                                 |
| **History of SCC and BCC prior to index SCC diagnosis**      |                               |                           |                                 |
| No                                                           | 7 (21.9)                     | 1 (2.0)                   | 0.005\(^2\)                    |
| Yes                                                          | 25 (78.1)                    | 49 (98.0)                 |                                 |
| **Number of HPV types in index SCC tumors**                 |                               |                           |                                 |
| 0                                                            | 23 (42.6)                    | 22 (28.6)                 | 0.17                           |
| 1                                                            | 12 (22.2)                    | 14 (18.2)                 |                                 |
| 2–5                                                          | 17 (31.5)                    | 33 (42.9)                 |                                 |
| >5                                                           | 2 (3.7)                      | 8 (10.4)                  |                                 |

\(^1\) Student’s \(t\)-test. \(^2\) Fisher’s exact test.

primary SCC, or second primary SCCs and the analyses stratified by these two outcomes were not conducted due to small sample. Conversely, combining recurrent and second primary SCCs as one outcome may have attenuated the true effect of HPV infection in index SCC on the development of recurrent or second primary SCCs.

The study has several strengths. To our knowledge, this is the first prospective study reporting an association between cutaneous HPV infection in SCC cases and subsequent SCCs. Of the 173 SCC cases enrolled in the parent case-control study, 86.7% cases were included in the present analyses highlighting complete follow-up on a large proportion of the cases. Since 92.8% SCC cases reported a prior history of SCC, the findings from our study may help further prognostic stratification of these SCCs using a biomarker of infection. These cases may represent ideal candidates to direct infection related prevention measures due to the high morbidity associated with risk of developing subsequent SCCs among SCCs. Based on the observed inverse association between HPV seropositivity and risk of subsequent SCC (Table 3), although not significant, immune response against HPV may protect against the development of subsequent...
Table 3: Association of seropositivity to cutaneous human papillomavirus (HPV) types at the time of the diagnosis of index SCC and risk of subsequent squamous cell carcinoma (SCC) of the skin.

| Viral Infection at the Time of the Index SCC Diagnosis | No Subsequent SCC (n = 59) | Subsequent SCC (n = 91) | HR (95% CI)* |
|------------------------------------------------------|---------------------------|------------------------|-------------|
| **Any cutaneous HPV**<sup>1</sup>                  |                           |                        |             |
| Seronegative to 33 cutaneous HPV types                | 6 (10.2)                  | 9 (9.9)                | 1.00        |
| Seropositive to ≥1 cutaneous HPV                      | 53 (89.8)                 | 82 (90.1)              | 0.83 (0.41–1.67) |
| **Alpha cutaneous HPV**                              |                           |                        |             |
| Seronegative to 33 cutaneous HPV types                | 6 (21.4)                  | 9 (20.4)               | 1.00        |
| Alpha HPV seropositive<sup>2</sup>                   | 22 (78.6)                 | 35 (79.6)              | 0.86 (0.40–1.82) |
| Alpha HPV seronegative                                | 37 (62.7)                 | 56 (61.5)              |             |
| Alpha HPV seropositive<sup>3</sup>                   | 22 (37.3)                 | 35 (38.5)              | 1.04 (0.68–1.59) |
| **Beta HPV**                                          |                           |                        |             |
| Seronegative to 33 cutaneous HPV types                | 6 (12.0)                  | 9 (12.0)               | 1.00        |
| Beta HPV seropositive<sup>2</sup>                    | 44 (88.0)                 | 66 (88.0)              | 0.80 (0.39–1.62) |
| Beta HPV seronegative                                 | 15 (25.4)                 | 25 (27.5)              | 1.00        |
| Beta HPV seropositive<sup>3</sup>                    | 44 (74.6)                 | 66 (72.5)              | 0.82 (0.51–1.30) |
| **Any beta 1 HPV**<sup>4</sup>                       |                           |                        |             |
| Seronegative                                          | 6 (17.6)                  | 9 (16.4)               | 1.00        |
| Beta 1 HPV seropositive                              | 28 (82.3)                 | 46 (83.6)              | 0.77 (0.37–1.59) |
| **Any beta 2 HPV**<sup>5</sup>                       |                           |                        |             |
| Seronegative                                          | 6 (17.6)                  | 9 (15.0)               | 1.00        |
| Beta 2 HPV seropositive                              | 28 (82.3)                 | 51 (85.0)              | 0.99 (0.48–2.04) |
| **Multiple beta 1 HPV**<sup>6</sup>                  |                           |                        |             |
| Seronegative                                          | 18 (52.9)                 | 24 (43.6)              | 1.00        |
| Seropositive to ≥2 beta 1 HPV                        | 16 (47.1)                 | 31 (56.4)              | 1.06 (0.61–1.83) |
| **Multiple beta 2 HPV**<sup>7</sup>                  |                           |                        |             |
| Seronegative                                          | 18 (52.9)                 | 25 (41.7)              | 1.00        |
| Seropositive to ≥2 beta 2 HPV                        | 16 (47.1)                 | 35 (58.3)              | 0.98 (0.58–1.67) |
| **Gamma HPV**                                         |                           |                        |             |
| Seronegative                                          | 6 (15.0)                  | 9 (13.2)               | 1.00        |
| Gamma HPV Seropositive                               | 34 (85.0)                 | 59 (86.8)              | 0.93 (0.46–1.90) |
| **Mu HPV**                                            |                           |                        |             |
| Seronegative                                          | 6 (22.2)                  | 9 (20.5)               | 1.00        |
| Mu HPV seropositive<sup>4</sup>                      | 21 (77.8)                 | 35 (79.5)              | 0.78 (0.37–1.65) |
| **Nu HPV**                                            |                           |                        |             |
| Seronegative                                          | 6 (66.7)                  | 9 (39.1)               | 1.00        |
| Nu HPV seronegative                                   | 3 (33.3)                  | 14 (60.9)              | 0.96 (0.38–2.44) |
| Seropositive                                          | 56 (94.9)                 | 77 (84.6)              | 1.00        |
| Seropositive                                          | 3 (5.1)                   | 14 (15.4)              | 1.31 (0.73–2.34) |

<sup>1</sup>Seropositivity to any cutaneous HPV (n = 33 types) versus negative to all. <sup>2</sup>Seropositive to at least one genus specific type versus negative to all cutaneous (n = 33) types. <sup>3</sup>Seropositive to at least one beta 1 type versus seronegative to 33 cutaneous HPV types. <sup>4</sup>Seropositive to at least one bet1 HPV type versus seronegative to all cutaneous types or positive to at least one beta 1 HPV type. <sup>5</sup>Seropositive to ≥2 beta 2 HPV types versus seronegative to all cutaneous types or positive to at least one beta 2 HPV type. <sup>6</sup>Seropositive to ≥2 beta 2 HPV types versus seronegative to all cutaneous types or positive to at least one beta 2 HPV type. HR = hazards ratio, CI = confidence interval. *Adjusted for age and gender.
Table 4: Association between cutaneous human papillomavirus (HPV) infection in eyebrow hair and the risk of subsequent squamous cell carcinoma (SCC).

| Eyebrow hair viral infection at the index SCC diagnosis | No subsequent SCC (n = 59) | Subsequent SCC (n = 91) | *HR (95% CI) |
|--------------------------------------------------------|---------------------------|-------------------------|-------------|
| **Any beta HPV**<sup>1,1</sup>                          |                           |                         |             |
| DNA negative                                           | 6 (10.5)                  | 12 (13.6)               | 1.00        |
| DNA positive                                           | 51 (89.5)                 | 76 (86.4)               | 0.84 (0.45–1.56) |
| **Any beta 1 HPV**<sup>2</sup>                         |                           |                         |             |
| DNA negative                                           | 6 (13.6)                  | 12 (16.2)               | 1.00        |
| DNA positive                                           | 38 (86.4)                 | 62 (83.8)               | 0.84 (0.44–1.58) |
| **Any beta 2 HPV**<sup>3</sup>                         |                           |                         |             |
| DNA negative                                           | 6 (12.0)                  | 12 (16.2)               | 1.00        |
| DNA positive                                           | 44 (88.0)                 | 62 (83.8)               | 0.85 (0.45–1.59) |
| **Multiple beta 1 HPV**<sup>4</sup>                    |                           |                         |             |
| DNA negative                                           | 25 (56.8)                 | 37 (50.0)               | 1.00        |
| DNA positive                                           | 19 (43.2)                 | 37 (50.0)               | 1.18 (0.72–1.93) |
| **Multiple beta 2 HPV**<sup>5</sup>                    |                           |                         |             |
| DNA negative                                           | 29 (58.0)                 | 35 (47.3)               | 1.00        |
| DNA positive                                           | 21 (42.0)                 | 39 (52.7)               | 1.23 (0.75–2.01) |

<sup>1</sup>Eyebrow hair DNA positive to any beta HPV type versus negative to all 25 beta HPV types.  
<sup>2</sup>Eyebrow hair DNA positive to at least one beta 1 HPV type versus DNA negative to 25 beta HPV types.  
<sup>3</sup>Eyebrow hair DNA positive to at least one beta 2 HPV type versus DNA negative to 25 beta HPV types.  
<sup>4</sup>Eyebrow hair DNA positive to 2 or more beta-1 HPV types versus DNA negative to 25 beta HPV types or positive to one beta 1 HPV type.  
<sup>5</sup>Eyebrow hair DNA positive to 2 or more beta 2 HPV types versus DNA negative to 25 beta HPV types or positive to one beta 2 HPV type. HR = hazards ratio, CI = confidence interval.  
*Adjusted for age and gender.

Table 5: Association of beta HPV infection in eyebrow hair and beta HPV seropositivity with the risk of subsequent SCC by index tumor HPV DNA status.

| Viral infection at the time of index SCC diagnosis | HPV DNA negative index SCC | HPV DNA positive index SCC |
|---------------------------------------------------|---------------------------|----------------------------|
|                                                   | No subsequent SCC (n = 23) | Subsequent SCC (n = 22) (95% CI) | No subsequent SCC (n = 31) | Subsequent SCC (n = 55) (95% CI) |
| HPV serology                                      |                           | HR                          |                           | HR                          |
| **Any beta HPV**<sup>1,3</sup>                    |                           |                             |                           |                             |
| Beta HPV seronegative                             | 7 (30.4)                  | 10 (45.5)                  | 1.00 (0.38–1.03)         | 7 (22.6)                  | 12 (21.8)                  | 1.00 (0.48–1.75)         |
| Beta HPV seropositive                             | 16 (69.6)                 | 12 (54.5)                  | 0.44 (0.18–2.50)        | 24 (77.4)                 | 43 (78.9)                  | 0.92 (0.11–0.78)        |
| HPV infection in eyebrow hairs                   |                           |                             |                           |                             |
| **Any beta HPV**<sup>2,3</sup>                    |                           |                             |                           |                             |
| DNA negative to all beta HPV types                | 3 (13.6)                  | 6 (27.3)                  | 1.0 (0.38–2.50)         | 2 (6.7)                   | 5 (9.4)                   | 1.0 (0.09–5.45)        |
| DNA positive to ≥1 beta HPV                       | 19 (86.4)                 | 16 (72.7)                  | 0.97 (0.45–3.24)       | 28 (93.3)                 | 48 (90.6)                 | 0.32 (0.12–0.86)       |
| **Any beta 1 HPV**<sup>4</sup>                    |                           |                             |                           |                             |
| DNA negative                                      | 3 (25.00)                 | 6 (33.3)                  | 1.0 (0.45–3.24)        | 2 (11.1)                  | 1 (2.8)                   | 1.0 (0.09–5.45)        |
| DNA positive                                      | 9 (75.0)                  | 12 (66.7)                 | 1.21 (0.31–2.32)       | 16 (88.9)                 | 35 (97.2)                 | 0.72 (0.09–5.45)       |
| **Any beta 2 HPV**<sup>4</sup>                    |                           |                             |                           |                             |
| DNA negative                                      | 3 (15.0)                  | 6 (35.3)                  | 1.0 (0.31–2.32)        | 1 (4.8)                   | 5 (12.8)                  | 1.0 (0.09–5.45)        |
| DNA positive                                      | 17 (85.0)                 | 11 (64.7)                 | 0.85 (0.12–0.86)       | 20 (95.2)                 | 34 (87.2)                 | 0.32 (0.12–0.86)       |

<sup>1</sup>Any beta HPV seropositivity was defined as seropositive to ≥1 beta HPV types versus seronegative to all beta HPV types.  
<sup>2</sup>Any beta HPV infection in eyebrow hairs was defined as DNA positivity to ≥1 beta HPV types versus DNA negativity to all beta HPV types.  
<sup>3</sup>Tumor DNA status was defined as DNA positive to one or more beta HPV types versus DNA negative to all beta HPV types.  
<sup>4</sup>Tumor DNA status was defined as DNA positivity to species-specific beta HPV types versus DNA negative to all beta HPV types.
SCCs. Thus, acquired immunity through vaccination against cutaneous HPV could potentially be explored among SCC cases. Additional strengths of this study include, examination of biomarkers of both, present HPV infection (eyebrow hair DNA and HPV serology) and past HPV infection (HPV serology) and evaluation of HPV infection as a prognostic marker by HPV genera and species.

4. Conclusion

In conclusion, the results from our prospective cohort study suggest that cutaneous HPV infection in eyebrow hairs is inversely associated with the development of subsequent SCCs in a subset of SCC cases with HPV DNA positive tumors. The observed association supports previous reports of lack of a role for cutaneous HPV infection in progression of SCCs. While cutaneous HPV may not be directly involved in the prognosis of SCC, this line of research may eventually lead to discovery of underlying immunological factors involved in SCC development and progression. Cutaneous HPV infection status could potentially be used as a biomarker for prognostic stratification of SCCs.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The parent case-control study was supported by a Florida Biomedical grant awarded to Dana E. Rollison (06NIR-08). This research was also supported in part by the Miles for Moffitt Foundation Funds and by the Tissue Core and Survey Core at H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292). The authors thank Kristen Jonathan, Jill Weber, Carolyn Gerow, and the USF/LCS staff for assistance with patient recruitment, and Monika Junk for technical assistance during the parent case-control study.

References

[1] M. Alam and D. Ratner, “Cutaneous squamous-cell carcinoma,” *New England Journal of Medicine*, vol. 344, no. 13, pp. 975–983, 2001.
[2] R. M. Lucas, A. J. Mcmichael, B. K. Armstrong, and W. T. Smith, “Estimating the global disease burden due to ultraviolet radiation exposure,” *International Journal of Epidemiology*, vol. 37, no. 3, pp. 654–667, 2008.
[3] M. R. Iannacone, T. Gheit, H. Pfister et al., “Case-control study of genus-beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma,” *International Journal of Cancer*, vol. 134, no. 9, pp. 2231–2244, 2014.
[4] M. R. Iannacone, T. Gheit, T. Waterboer et al., “Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 21, no. 8, pp. 1303–1313, 2012.
[5] M. R. Iannacone, W. Wang, H. G. Stockwell et al., “Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin,” *Journal of Infectious Diseases*, vol. 206, no. 3, pp. 399–406, 2012.
[6] J. N. Bouwes Bavinck, R. E. Neale, D. Abeni et al., “Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma,” *Cancer Research*, vol. 70, no. 23, pp. 9777–9786, 2010.
[7] C. M. Proby, C. A. Harwood, R. E. Neale et al., “A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients,” *American Journal of Transplantation*, vol. 11, no. 7, pp. 1498–1508, 2011.
[8] L. Struikj, J. N. B. Bavinck, P. Wanningen et al., “Presence of human papillomavirus DNA in plucked eyebrow hairs is associated with a history of cutaneous squamous cell carcinoma,” *Journal of Investigative Dermatology*, vol. 121, no. 6, pp. 1531–1535, 2003.
[9] M. R. Karagas, H. H. Nelson, P. Sehr et al., “Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin,” *Journal of the National Cancer Institute*, vol. 98, no. 6, pp. 389–395, 2006.
[10] C. Prieto-Granada and P. Rodriguez-Waitkus, “Cutaneous squamous cell carcinoma and related entities: epidemiology, clinical and histological features, and basic science overview,” *Current Problems in Cancer*, vol. 39, no. 4, pp. 206–215, 2015.
[11] T. R. Mcrackan, T.-Y. Fang, S. Pelosi et al., “Factors associated with recurrence of squamous cell carcinoma involving the temporal bone,” *Annals of Otology, Rhinology and Laryngology*, vol. 123, no. 4, pp. 235–239, 2014.
[12] M. J. Veness, C. E. Palme, and G. J. Morgan, “High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease,” *Cancer*, vol. 106, no. 11, pp. 2389–2396, 2006.
[13] J. C. Melo, M. E. A. Marques, L. Vasconcelos, H. A. Miot, and L. P. F. Abbade, “Invasive head and neck cutaneous squamous cell carcinoma: clinical and histopathological characteristics, frequency of local recurrence and metastasis,” *Anais Brasileiros de Dermatologia*, vol. 89, no. 4, pp. 562–568, 2014.
[14] C. Wassberg, M. Thörn, J. Yuen, U. Ringborg, and T. Hakulinen, “Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden,” *International Journal of Cancer*, vol. 80, no. 4, pp. 511–515, 1999.
[15] I. Marci and R. S. Stern, “Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis,” *Archives of Dermatology*, vol. 136, no. 12, pp. 1524–1530, 2000.
[16] D. E. Rollison, A. R. Giuliani, J. L. Messina et al., “Case-control study of Merkel cell polyomavirus infection and cutaneous squamous cell carcinoma,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 21, no. 1, pp. 74–81, 2012.
[17] P. Sehr, M. Müller, R. Höpfl, A. Widschwendter, and M. Pawlita, “HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase,” *Journal of Virological Methods*, vol. 106, no. 1, pp. 61–70, 2002.
[18] P. Sehr, K. Zumbach, and M. Pawlita, “A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology,” *Journal of Immunological Methods*, vol. 253, no. 1-2, pp. 153–162, 2001.
[19] T. Waterboer, P. Sehr, K. M. Michael et al., “Multiplex human papillomavirus serology based on in situ-purified glutathione
S-transferase fusion proteins,” *Clinical Chemistry*, vol. 51, no. 10, pp. 1845–1853, 2005.

[20] T. Gheit, G. Billoud, M. N. C. De Koning et al., “Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect betapapillomavirus types,” *Journal of Clinical Microbiology*, vol. 45, no. 8, pp. 2537–2544, 2007.

[21] J. B. Ruer, L. Pépin, T. Gheit et al., “Detection of alpha- and beta-human papillomavirus (hpv) in cutaneous melanoma: a matched and controlled study using specific multiplex pcr combined with dna microarray primer extension,” *Experimental Dermatology*, vol. 18, no. 10, pp. 857–862, 2009.

[22] M. R. Karagas, E. R. Greenberg, S. K. Spencer, T. A. Stukel, and L. A. Mott, “Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA;” *International Journal of Cancer*, vol. 81, no. 4, pp. 555–559, 1999.

[23] M. Sugiyama, U. K. Bhawal, M. Kawamura et al., “Human papillomavirus-16 in oral squamous cell carcinoma: clinical correlates and 5-year survival,” *British Journal of Oral and Maxillofacial Surgery*, vol. 45, no. 2, pp. 116–122, 2007.

[24] K. R. Dahlstrom, G. Li, C. S. Hussey et al., “Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer,” *Cancer*, vol. 122, no. 3, pp. 489–489, 2016.

[25] J. M. Ritchie, E. M. Smith, K. F. Summersgill et al., “Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx;” *International Journal of Cancer*, vol. 104, no. 3, pp. 336–344, 2003.

[26] S. Atighechi, M. R. A. Baghdadabad, S. A. Mirvakili et al., “Human papilloma virus and nasopharyngeal carcinoma: pathology, prognosis, recurrence and mortality of the disease;” *Experimental Oncology*, vol. 36, no. 3, pp. 215–216, 2014.

[27] J. T. Schiller and C. B. Buck, “Cutaneous squamous cell carcinoma: a smoking gun but still no suspects,” *Journal of Investigative Dermatology*, vol. 131, no. 8, pp. 1595–1596, 2011.

[28] S. Jablonska, J. Dabrowski, and K. Jakubowicz, “Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis;” *Cancer Research*, vol. 32, no. 3, pp. 583–589, 1972.

[29] S. S. Hampras, D. E. Rollison, M. Tommasino et al., “Genetic variations in the epidermodysplasia verruciformis (EVER/TMC) genes, cutaneous human papillomavirus infection and squamous cell carcinoma of the skin;” *British Journal of Dermatology*, vol. 173, no. 6, pp. 1532–1535, 2016.